Navigation Links
SciClone To Present At Boston Biotech NY/NJ CEO Conference On November 12th
Date:11/3/2015

FOSTER CITY, Calif., Nov. 3, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will participate in a panel discussion at the Boston Biotech Conferences (BBC) NY/NJ CEO conference on November 12th, at the Apella in New York City.

The conference will focus on the 2016 healthcare industry outlook, disruptive innovation and venture philanthropy, non-dilutive financing, pricing and reimbursement, defining the value of drugs, innovation in drug discovery, personalized medicine, creative financing, emerging markets, innovative deal structures, and more. Dr. Blobel will participate in a panel titled, "Importance of Emerging Markets."

The Boston Biotech Conferences (BBC)'s mission is to build a vibrant community of biopharma leaders, which will help to drive biopharma innovation in biotech, by convening leaders across industry and academia. The conferences are exclusive, thought-leader forums for senior biopharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking, and corporate development within the biopharma community. For more information, visit: http://bbbiotechconference.com/conference-details.php?id=34

About SciClone

SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Through its promotion business with pharmaceutical partners, SciClone also markets multiple branded products in China which are therapeutically differentiated. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially.  Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.Corporate ContactsWilson W. CheungJane GreenChief Financial OfficerInvestors/Media650.358.3434650.358.1447wcheung@sciclone.comjgreen@sciclone.com

Logo - http://photos.prnewswire.com/prnh/20150722/240358LOGO

 


'/>"/>
SOURCE SciClone Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. SciClone To Present At Two Investor Conferences On September 10, 2015
2. SciClone To Present At 2015 Aegis Capital Growth Conference On October 9th
3. SciClone Pharmaceuticals To Report Financial Results For The Third Quarter 2015 On November 9th
4. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
5. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
6. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
7. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
8. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
9. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
10. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
11. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2020)... SEATTLE (PRWEB) , ... April 04, 2020 , ... ... turned their baby blanket manufacturing facility into a factory producing non-medical cloth facemasks. ... crisis strategy to approve the use of non-medical cloth face masks if no ...
(Date:4/5/2020)... ... 04, 2020 , ... As the world scrambles to handle ... and treatments. Shortages of such supplies are plaguing hospitals and care-givers, putting the ... Associates supports the fight against COVID-19 and encourages every-day citizens to apply their ...
(Date:4/2/2020)... SCOTTSDALE, Ariz. (PRWEB) , ... April 02, 2020 , ... ... their roles at the Meeting of the NCPDP Board of Trustees on Wednesday, May ... Pooja Babbrah, M.B.A., PBM Practice Lead, Point-of-Care Partners, newly elected to the ...
Breaking Medicine Technology:
(Date:4/2/2020)... NEW ORLEANS (PRWEB) , ... April 02, 2020 ... ... opioids while fetuses in their mother’s womb are encouraging their parents, grandparents, and ... compensation from Purdue—reportedly up to $6 billion in funds will be made available ...
(Date:4/1/2020)... ... , ... Medical Device Change Management, An FDAnews Webinar , Thursday, April 16, ... management method should one be using for a medical device? , The answer ... Is it due to post-market design change, production process changes, QMS process changes, corrective ...
(Date:4/1/2020)... , ... April 01, 2020 , ... ... (PPE) to stay safe while treating Coronavirus-infected patients. , Staffers are in particular ... can transmit coronavirus. Earlier this week, The Wall Street Journal reported that New ...
(Date:4/1/2020)... ... April 01, 2020 , ... Global mobile data platform ... for teams adjusting to new needs based on COVID-19. , As cases continue to ... of all types. , Zerion will extend support by offering free basic iFormBuilder accounts ...
(Date:3/30/2020)... ... March 30, 2020 , ... Achieve Medical Center now offers ... provide comprehensive and compassionate mental health and wellness services in the midst of ... for telemedicine services including initial consultations, evaluations, and follow-up care. It also allows ...
Breaking Medicine News(10 mins):